Results 271 to 280 of about 756,649 (382)

Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma [PDF]

open access: gold, 2015
Michiko Yamashita   +9 more
openalex   +1 more source

Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop

open access: yesHistopathology, 2015
A. Robson   +28 more
semanticscholar   +1 more source

HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions

open access: yesTransplant Infectious Disease, EarlyView.
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni   +9 more
wiley   +1 more source

TOX expression in cutaneous B-cell lymphomas [PDF]

open access: hybrid, 2016
Anne M.R. Schrader   +2 more
openalex   +1 more source

Extracorporeal photopheresis—New insights into an old procedure

open access: yesTransfusion Medicine, EarlyView.
Abstract Background Extracorporeal photopheresis (ECP) is a safe immunomodulatory strategy that induces cell‐type selective apoptosis through photodynamic processes. Despite decades of use, the mechanisms underlying ECP remain largely unexplored, particularly in studies examining specific immune cell subsets in ex vivo setups.
Sabine Seiffert   +10 more
wiley   +1 more source

Classification and clinical features in 88 cases of equine cutaneous lymphoma

open access: yesJournal of Veterinary Diagnostic Investigation, 2015
Craig A. Miller   +5 more
semanticscholar   +1 more source

Evaluating VEGFR2 as a Target for Anti‐Tumour Therapy in Canine Melanoma

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Vascular endothelial growth factor receptor 2 (VEGFR2) is a key target for anti‐angiogenic oncotherapy, as inhibiting this receptor on tumour vasculature slows tumour development and enhances drug‐ and immune infiltration, improving therapy outcome.
Esther Hindriks   +5 more
wiley   +1 more source

Corrigendum: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. [PDF]

open access: yesJ Eur Acad Dermatol Venereol, 2020
Papadavid E   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy